Pediatrics (System-Integrated)

Pediatric constipation: functional vs organic

Clinical Overview and When to Suspect Pediatric Constipation

— Affects ~3–5% of pediatric outpatient visits, up to 25% of pediatric GI referrals.

— Peaks at 3 transition points: introduction of solids, toilet training (2–4 yr), school entry (when kids avoid school bathrooms).

— >95% of cases are functional (no anatomic, metabolic, or neurologic cause).

— Organic causes (~5%): Hirschsprung disease, hypothyroidism, celiac, cystic fibrosis, anorectal malformation, spinal dysraphism, cow's milk protein allergy, lead toxicity, neuromuscular disease.

— Painful defecation → voluntary withholding → rectal distention → decreased rectal sensation → larger, harder stools → cycle perpetuates.

— Encopresis (fecal incontinence) results from overflow around impaction, not behavioral defiance — critical to frame for parents.

— Onset <1 month of life, delayed meconium >48 hr, failure to thrive, bilious vomiting, abdominal distention, ribbon stools, blood without fissure, abnormal anal placement or sacral dimple/tuft, absent cremasteric/anal wink, lower extremity weakness.

Board pearl: A toddler with painful stooling, soiling underwear daily, and a palpable suprapubic stool mass is functional constipation with overflow encopresis — not diarrhea, not abuse, not Hirschsprung. Treat with disimpaction + maintenance osmotic laxative, not antidiarrheals or invasive workup.

Definition (Rome IV, functional constipation): ≥2 of the following for ≥1 month in children <4 yr (or ≥2 months in ≥4 yr): ≤2 defecations/week, history of excessive stool retention, painful/hard stools, large-diameter stools, large fecal mass in rectum, ≥1 episode of incontinence/week after toilet training.

Epidemiology:

Functional vs organic — base rates:

Pathophysiology of functional constipation:

When to suspect organic cause ("red flags"):

Presentation Patterns and Key History

— Toddler/preschooler who hides during stooling (squatting, crossing legs, hiding behind furniture) — parents often misinterpret as straining to go when child is actually withholding.

— Hard, large-caliber stools that "clog the toilet."

— Stool refusal after a painful episode (fissure, illness, travel, toilet training pressure).

— Soiling in underwear in a previously continent child = overflow encopresis until proven otherwise.

— Breastfed infants can normally go 7–10 days without stooling if soft — not constipation.

— Infant dyschezia: straining/crying ≥10 min before passing soft stool in otherwise well infant <9 mo — benign, self-resolves, no treatment.

— Hard stools in formula-fed infants — consider cow's milk protein intolerance.

— Age of onset, timing of first meconium (>48 hr suggests Hirschsprung).

— Stool frequency, caliber, consistency (Bristol 1–2 = constipation).

— Pain, blood streaking, soiling episodes.

— Diet: fluid intake, fiber, excessive cow's milk (>24 oz/day is a classic culprit).

— Toilet training history, school bathroom avoidance.

— Growth trajectory (failure to thrive → organic).

— Family history of Hirschsprung, celiac, thyroid, cystic fibrosis.

— Psychosocial: stressors, abuse history, ADHD/autism (higher constipation rates).

Key distinction: Stool withholding posturing (rigid, on tiptoes, hiding) is often mistaken by parents and even clinicians for straining to defecate. Recognizing this reframes the diagnosis from "can't go" to "won't go" and changes the entire therapeutic conversation toward demystification and behavioral plus pharmacologic disimpaction.

Classic functional pattern:

Infant patterns (<1 yr):

Key history questions (Step 3 ambulatory framing):

Medications to ask about: opioids, anticholinergics, iron, antacids with aluminum, sympathomimetics.

Physical Exam Findings and Red-Flag Assessment

— Plot height, weight, BMI — failure to thrive is a red flag for celiac, CF, hypothyroidism, or Hirschsprung.

— Coarse features, bradycardia, cold intolerance → hypothyroidism.

— Palpable stool, especially in left lower quadrant or suprapubic area = fecal loading.

— Distention with visible loops or tympany — concerning for obstruction or megacolon.

— Anal position: anteriorly displaced anus is a structural cause.

— Fissures (most common cause of streak blood — confirms hard stool history).

— Perianal erythema, skin tags, fistulae → Crohn disease.

— Anal wink and cremasteric reflex — absent suggests tethered cord/spinal dysraphism.

— Sacral exam: dimple, hair tuft, lipoma, hemangioma, gluteal cleft deviation → spinal dysraphism.

— Not required at every visit but indicated when diagnosis is uncertain, before initiating long-term therapy, or red flags present.

— Functional: ampulla loaded with stool, normal tone.

— Hirschsprung clue: empty, tight ("tight rectum, empty vault"), and explosive stool/gas release on withdrawal of finger ("squirt sign").

— Lower extremity tone, strength, reflexes, gait — abnormal suggests spinal cord pathology.

Board pearl: The squirt sign on DRE — explosive release of stool/gas after withdrawing the examining finger from an empty, tight rectal vault in an infant — is the single most specific bedside clue to Hirschsprung disease and should trigger contrast enema followed by rectal suction biopsy rather than starting laxatives.

General/growth:

Abdominal exam:

Perianal/rectal inspection (essential, often skipped):

Digital rectal exam (DRE):

Neurologic:

Skin: café-au-lait spots (neurofibromatosis association with constipation), dry skin (hypothyroidism).

Diagnostic Workup — When (Not) to Order Labs and Imaging

— TSH, free T4 — if growth failure, fatigue, bradycardia, dry skin.

— Tissue transglutaminase IgA + total IgA — celiac screen, especially with abdominal pain, weight loss, anemia, or family history.

— Electrolytes, calcium, magnesium — if polyuria, polydipsia, weakness; hypercalcemia and hypokalemia slow gut.

— Lead level — if pica, housing risk, or developmental concerns.

— Sweat chloride — if recurrent respiratory issues, FTT, or steatorrhea.

— CBC — anemia suggests celiac, IBD, or chronic blood loss.

— Routine use is NOT recommended by NASPGHAN/ESPGHAN — poor reproducibility, radiation, and high false-positive "stool burden" reads.

— May be useful when: physical exam is unreliable (obesity, refusal), to confirm impaction before disimpaction protocol, or to assess response in refractory cases.

— Routine ultrasound, CT, MRI, colonoscopy, manometry, or transit studies for uncomplicated cases.

— Lumbosacral spine MRI → if sacral dimple/tuft, abnormal neuro exam, urinary retention.

— Contrast (water-soluble or barium) enema → suspected Hirschsprung (look for transition zone) or anatomic obstruction.

Step 3 management: A 4-year-old with classic withholding, soiling, and palpable stool mass needs no labs and no x-ray — start disimpaction with PEG 3350 and schedule a 2-week follow-up. Reflexively ordering an abdominal film or TSH on every constipated child is a common Step 3 distractor — choose clinical diagnosis + treatment.

Core principle: Functional constipation is a clinical diagnosis based on Rome IV criteria + reassuring exam. No routine labs or imaging needed.

Indications for targeted labs (red flags or treatment failure):

Plain abdominal radiograph:

What NOT to order initially:

Imaging red-flag triggers:

Diagnostic Workup — Confirmatory Studies for Organic Causes

— Contrast enema (unprepped): transition zone between narrow aganglionic distal segment and dilated proximal bowel; delayed barium retention >24 hr is suggestive.

— Anorectal manometry: absence of rectoanal inhibitory reflex (RAIR) — internal anal sphincter fails to relax with rectal distention. Useful in older children/short-segment disease.

— Gold standard: rectal suction biopsy showing absent ganglion cells in submucosal/myenteric plexus and hypertrophied nerve trunks (with positive acetylcholinesterase staining).

— Anorectal malformation — physical exam + perineal inspection; fluoroscopic distal colostogram if colostomy in place.

— Spinal ultrasound in infants <3 months (before vertebral ossification).

— MRI lumbosacral spine in older children or when ultrasound abnormal.

— Colonic transit study (radiopaque markers or scintigraphy) — distinguishes slow-transit constipation from outlet dysfunction.

— Anorectal manometry — evaluates dyssynergic defecation.

— Defecography — rarely needed in pediatrics.

— Cow's milk protein elimination trial (2–4 wk dietary trial) — diagnostic and therapeutic in select infants/toddlers.

— Stool studies if infectious overlap or IBD suspicion (calprotectin, occult blood).

Key distinction: Hirschsprung vs functional constipation on history — Hirschsprung presents in neonates with delayed meconium passage >48 hr, no soiling, empty rectum on DRE, and FTT; functional presents in toddlers with painful stooling, frequent soiling (encopresis), and a stool-loaded rectum. Encopresis essentially rules out Hirschsprung.

Suspected Hirschsprung disease:

Suspected anatomic anomaly:

Suspected spinal dysraphism/tethered cord:

Refractory functional constipation workup (after failed 6+ months optimal therapy):

Specific etiology testing:

Management Logic — Two-Phase Approach

— 1) Education and demystification (parent buy-in is essential).

— 2) Disimpaction (clear the rectum).

— 3) Maintenance (months of laxatives + behavioral plan).

— 4) Behavioral therapy (toilet sitting, rewards, school accommodations).

— Explain withholding cycle and that encopresis is involuntary overflow, not misbehavior — eliminates punishment, restores child's self-esteem.

— Set expectation: treatment takes 6–24 months; relapse is common.

— Frame as a medical condition, not parenting failure.

— Oral PEG 3350 (polyethylene glycol): 1–1.5 g/kg/day for 3–6 days — first-line, highest evidence.

— Alternative: high-dose mineral oil (>1 yr only, aspiration risk).

— Rectal route (enemas, suppositories) — reserved for refractory or rapid clearance; many children refuse, can be traumatic.

— Hospitalization for nasogastric PEG only if outpatient fails or severe impaction with vomiting.

— PEG 3350, 0.4–0.8 g/kg/day, titrated to 1–2 soft stools daily.

— Continue at least 2 months after symptoms resolve, then taper slowly.

— Add behavioral plan: scheduled post-meal toilet sits (5–10 min, 2–3×/day) leveraging gastrocolic reflex, footstool for hip flexion.

CCS pearl: On a CCS-style case, order "PEG 3350 disimpaction → maintenance dose", schedule 2-week follow-up, and add "counsel parents on encopresis, scheduled toilet sits, dietary fluid/fiber, limit milk to 16–24 oz/day" — these advance the clock and earn management credit.

Step 3 framework: every functional constipation plan has 4 components:

Education priorities:

Disimpaction (1–7 days):

Maintenance (≥6 months, often longer):

Diet: age-appropriate fluid and fiber, limit cow's milk to <24 oz/day, normalize rather than force fiber.

Pharmacotherapy — First-Line and Adjunctive Agents

— Osmotic laxative; not absorbed; safe long-term per NASPGHAN.

— Disimpaction: 1–1.5 g/kg/day × 3–6 days (max 100 g/day).

— Maintenance: 0.4–0.8 g/kg/day, titrate to soft daily stool.

— Side effects: bloating, gas, transient diarrhea, rare electrolyte shifts at very high doses.

— Mix in any beverage; tasteless — improves adherence.

— Alternative when PEG unavailable or in infants <6 months.

— 1–2 g/kg/day divided BID; flatulence and cramping common.

— Lubricant; ≥1 year only (aspiration risk → lipoid pneumonia).

— Maintenance: 1–3 mL/kg/day; can decrease fat-soluble vitamin absorption.

— Senna (2–6 yr: 2.5–7.5 mg/day; 6–12 yr: 7.5–15 mg/day) or bisacodyl (5–10 mg/day).

— Use for breakthrough or as adjunct in refractory cases; no longer considered habit-forming at appropriate doses.

— Glycerin suppositories (infants), bisacodyl suppositories, saline or mineral oil enemas.

— Avoid sodium phosphate enemas in <2 yr and in renal impairment — risk of hyperphosphatemia, hypocalcemia, tetany.

— Lubiprostone, linaclotide, prucalopride — limited pediatric data; reserved for tertiary care.

— Glycerin suppositories PRN, lactulose, sorbitol-containing juices (prune, pear, apple) after 4 months.

Board pearl: Avoid Fleet (sodium phosphate) enemas in children <2 years and in renal disease — life-threatening hyperphosphatemia, hypocalcemia, and hypernatremia have caused fatalities. Use saline or mineral oil enemas instead, or oral PEG.

PEG 3350 (polyethylene glycol, MiraLAX) — first-line at every age >6 months:

Lactulose:

Mineral oil:

Stimulant laxatives (rescue/short-term adjunct):

Rectal therapies (disimpaction only, avoid chronic use):

Newer agents (refractory cases, specialty use):

Infant-specific options:

Refractory Constipation and Procedural Management

— Reassess adherence and dose (most "refractory" cases are under-dosed PEG).

— Re-examine for missed organic causes (recheck TSH, celiac panel, spine exam).

— Anorectal manometry to evaluate for dyssynergic defecation or short-segment Hirschsprung.

— Colonic transit study to differentiate slow-transit vs normal-transit vs outlet dysfunction.

— Biofeedback therapy — for dyssynergic defecation in older children.

— Pelvic floor physical therapy.

— Transanal irrigation — daily/alternate-day rectal irrigations; very effective in spina bifida, anorectal malformations, refractory functional cases.

— Antegrade continence enemas (ACE/Malone procedure): appendicostomy or cecostomy tube for daily flushes; markedly improves quality of life in refractory or neurogenic bowel.

— Sacral nerve stimulation — emerging option for refractory adolescents.

— Segmental colectomy for documented isolated segment dysmotility.

— Subtotal colectomy with ileorectal anastomosis — last resort for severe slow-transit constipation.

— Hirschsprung pull-through procedures (Soave, Swenson, Duhamel) — definitive for confirmed aganglionosis.

Step 3 management: A 10-year-old on appropriate PEG for 4 months with persistent soiling and a stool-loaded rectum — first re-verify adherence, optimize dose, and reinforce behavioral plan before referral. The most common cause of "treatment failure" is under-dosing PEG and stopping it as soon as symptoms improve. Continue maintenance therapy 2 months past symptom resolution, then taper.

Definition of refractory: failure to respond to 3+ months of optimized oral therapy with adherence confirmed.

Workup before escalation:

Specialty interventions:

Surgical options (rare, after exhaustive medical therapy):

Botulinum toxin injection to internal anal sphincter — for nonrelaxing sphincter on manometry.

Special Populations — Comorbid Chronic Disease and Renal/Hepatic Considerations

— Avoid magnesium-containing laxatives (milk of magnesia, magnesium citrate) — risk of hypermagnesemia.

— Avoid sodium phosphate enemas/oral preparations — life-threatening hyperphosphatemia and acute phosphate nephropathy.

— PEG 3350 is safe — minimal systemic absorption.

— Lactulose acceptable.

— Lactulose is therapeutic (reduces ammonia in hepatic encephalopathy) and safe.

— Avoid mineral oil if portal hypertension/coagulopathy (variceal irritation).

— PEG safe.

— Higher baseline prevalence of constipation (sensory, motility, immobility, restricted diets).

— Lower threshold for scheduled (not PRN) laxatives.

— Down syndrome — screen for Hirschsprung (increased association) and hypothyroidism.

— Autism — sensory aversion to toileting; rigid routines may help.

— Bowel management program: scheduled enemas, transanal irrigation, ACE procedure.

— Goal: social continence with planned evacuation.

— Distinguish constipation from distal intestinal obstruction syndrome (DIOS) — DIOS presents with right lower quadrant mass, vomiting, obstruction; treat with PEG large volumes or Gastrografin enema, optimize pancreatic enzymes.

— Prophylactic stimulant + osmotic laxative when starting opioids; methylnaltrexone for refractory opioid-induced constipation.

Key distinction: In a CF patient with abdominal pain and a palpable RLQ mass, DIOS — not simple constipation — is the diagnosis, and treatment requires high-volume PEG lavage or Gastrografin, plus reassessment of pancreatic enzyme dosing and adherence. Routine maintenance laxative therapy alone is insufficient.

Children with chronic kidney disease:

Children with hepatic dysfunction:

Neurodevelopmental disabilities (cerebral palsy, autism, Down syndrome):

Spina bifida / neurogenic bowel:

Cystic fibrosis:

Oncology/opioid-induced:

Special Populations — Infants and Adolescents

— Rome IV criteria differ — emphasis on hard stools and pain.

— Infant dyschezia (straining + crying ≥10 min then soft stool, well infant): reassurance only, self-resolves by 6–9 mo. No rectal stimulation, no laxatives.

— True constipation in this age: consider cow's milk protein intolerance (trial 2–4 wk extensively hydrolyzed formula), Hirschsprung, hypothyroidism (review newborn screen), cystic fibrosis, anorectal malformation.

— First-line agents: lactulose, sorbitol-containing juices (prune/pear/apple, 2–4 oz/day after 4 months), glycerin suppositories PRN.

— Avoid mineral oil (<1 yr) and stimulant laxatives.

— Toilet training pressure is a leading trigger — pause training, restart when child is ready.

— Limit cow's milk to <24 oz/day (excess milk → reduced appetite for fiber, casein-bound stool).

— PEG 3350 first-line.

— School bathroom avoidance is huge — write a school letter for unrestricted bathroom access.

— Encopresis often emerges here; address shame and bullying.

— Consider eating disorders, depression, opioid/cannabinoid use, anabolic steroid abuse (laxative misuse can be either cause or compensation).

— Screen for sexual abuse if pain, anal trauma, or sudden withholding behavior.

— Pregnancy: PEG and lactulose are safe; avoid stimulants chronically, avoid mineral oil and castor oil.

Board pearl: A thriving 3-month-old who cries and strains for 10 minutes before passing a soft, normal-volume stool has infant dyschezia — the answer is parental reassurance and avoidance of rectal stimulation, not laxatives, suppositories, or imaging. Rectal stimulation prevents the infant from learning coordinated defecation.

Infants <6 months:

Toddlers (1–4 yr):

School-age (5–12 yr):

Adolescents:

Complications and Adverse Outcomes

— Most common complication; cause of bright red blood streaking stool.

— Perpetuates the withholding cycle through pain.

— Treat with stool softening, sitz baths, barrier ointment.

— Affects ~80% of children with chronic constipation.

— Major social, emotional, academic toll — bullying, school avoidance, low self-esteem.

— Suggests chronic straining; in a child with rectal prolapse, always check sweat chloride for cystic fibrosis.

— Enuresis (especially nocturnal), UTIs, vesicoureteral reflux — full rectum compresses bladder neck and reduces functional capacity.

— Treating constipation often resolves enuresis/UTI recurrence.

— Rare; severe prolonged impaction can cause ischemic ulceration of rectosigmoid.

— Chronic distention → impaired rectal sensation → harder to retrain; underscores need for prolonged maintenance.

— Anxiety, school refusal, oppositional behavior often resolve with successful treatment.

— Family conflict (over toileting, soiling) — address with anticipatory guidance.

— Electrolyte disturbances from sodium phosphate enemas.

— Lipoid pneumonia from aspirated mineral oil.

— Bowel perforation from forceful enema administration.

— Severe chronic constipation can suppress appetite → poor growth.

Key distinction: Recurrent UTIs or new-onset daytime/nighttime enuresis in a constipated child — treat the constipation first. This "bowel-bladder dysfunction" complex resolves in the majority of children once normal bowel patterns are restored, and missing it leads to unnecessary urologic workup and antibiotic exposure.

Anal fissures:

Overflow fecal incontinence (encopresis):

Rectal prolapse:

Urinary complications:

Stercoral ulceration and perforation:

Acquired megacolon:

Psychosocial/behavioral:

Iatrogenic complications:

Failure to thrive (rare):

When to Escalate Care — Consult, Imaging, or Admission

— Failure of 3–6 months of optimized therapy with confirmed adherence.

— Suspected organic etiology (red flags, abnormal exam, FTT).

— Refractory encopresis despite appropriate disimpaction and maintenance.

— Need for anorectal manometry, transit studies, or biopsy.

— Suspected Hirschsprung disease — for rectal biopsy and definitive surgery.

— Anorectal malformation, anal stenosis, anterior anus.

— Consideration of antegrade continence enema (ACE/cecostomy) for refractory cases.

— Abnormal lower extremity neuro exam, sacral findings, or MRI abnormality (tethered cord).

— Persistent bowel-bladder dysfunction after constipation is controlled; recurrent UTIs with reflux.

— Confirmed hypothyroidism or other endocrinopathy.

— Toilet phobia, anxiety, oppositional refusal, or family conflict undermining treatment.

— Suspected abuse.

— Severe impaction with vomiting, dehydration, or failed outpatient disimpaction.

— Nasogastric PEG lavage requirement.

— Suspected bowel obstruction, intussusception, or perforation.

— Severe electrolyte derangements from prior therapy.

— Hirschsprung-associated enterocolitis (fever, abdominal distention, explosive bloody diarrhea, sepsis) — medical emergency requiring resuscitation, decompression, broad-spectrum antibiotics, and urgent surgical evaluation.

CCS pearl: In a constipated child with fever, abdominal distention, lethargy, and foul explosive diarrhea, recognize Hirschsprung-associated enterocolitis (HAEC) — order IV fluids, broad-spectrum antibiotics (including anaerobic coverage), NPO, rectal decompression, and emergent surgical consult. Mortality is significant if missed.

Pediatric GI referral indications:

Pediatric surgery referral:

Neurology/neurosurgery referral:

Urology referral:

Endocrinology:

Mental health / behavioral pediatrics:

Inpatient admission indications:

Emergent surgical consult:

Key Differentials — Other GI/Colorectal Causes

— Neonatal onset, delayed meconium >48 hr, empty rectal vault, squirt sign, no soiling, FTT.

— Diagnosis: contrast enema (transition zone), manometry (absent RAIR), rectal suction biopsy (definitive).

— Short-segment forms can present later in childhood but never with encopresis.

— Anteriorly displaced anus, anal stenosis, imperforate anus variants — diagnosed on inspection at birth or with persistent constipation.

— Recurrent obstructive episodes without mechanical cause; abnormal manometry; often with bladder dysmotility.

— Stricturing disease can present with constipation; perianal disease (tags, fistulae) is a clue.

— Weight loss, anemia, elevated inflammatory markers.

— More commonly diarrhea, but ~10–20% present with constipation, abdominal distention, FTT.

— Screen with tTG IgA + total IgA.

— Meconium ileus in neonate; DIOS in older children; rectal prolapse.

— Newborn screening catches most; confirm with sweat chloride.

— Infants/toddlers with constipation, sometimes blood streaking; trial of extensively hydrolyzed formula or maternal dairy elimination 2–4 weeks.

— Usually a perpetuator, occasionally the inciting cause.

Board pearl: Delayed meconium passage >48 hours after birth in a term infant is the single most discriminating historical feature for Hirschsprung disease — over 90% of neonates with Hirschsprung fail to pass meconium in the first 48 hours, whereas <10% of healthy term infants do.

Hirschsprung disease:

Anorectal malformation:

Intestinal pseudo-obstruction (chronic):

Inflammatory bowel disease (Crohn especially):

Celiac disease:

Cystic fibrosis:

Cow's milk protein allergy/intolerance:

Anal fissure with secondary withholding:

Key Differentials — Endocrine, Metabolic, Neurologic, and Toxic

— Constipation, growth deceleration, cold intolerance, fatigue, dry skin, bradycardia, delayed reflexes.

— Check TSH and free T4; congenital cases caught on newborn screen but acquired (Hashimoto) presents in school-age/adolescence.

— Constipation, polyuria, weakness, altered mental status.

— Causes: hyperparathyroidism, vitamin D toxicity, malignancy, Williams syndrome, immobilization.

— Ileus/constipation; assess for laxative or diuretic misuse (especially adolescent with eating disorder).

— Autonomic neuropathy in long-standing disease can cause gastroparesis and constipation.

— Constipation, abdominal pain, anemia, developmental regression, pica; check blood lead level.

— Tethered cord, lipomyelomeningocele, spinal tumor, transverse myelitis.

— Clues: sacral dimple/tuft, abnormal gait, urinary retention, asymmetric reflexes.

— Constipation is often the first symptom, followed by descending paralysis, weak cry, poor feeding, hypotonia in infants <12 months. Treat with BabyBIG (human botulism immune globulin).

— Opioids, anticholinergics (TCAs, antihistamines, antipsychotics), iron, aluminum antacids, sucralfate, ondansetron, calcium channel blockers, vincristine.

— Autism spectrum (sensory aversion), depression, anorexia nervosa (laxative misuse, slow transit).

Key distinction: A previously well 4-month-old with new constipation, poor feeding, weak cry, and progressive hypotonia is infant botulism until proven otherwise — not functional constipation. Send stool for C. botulinum toxin/spores, admit, and administer BabyBIG promptly; avoid aminoglycosides (potentiate neuromuscular block).

Hypothyroidism:

Hypercalcemia:

Hypokalemia:

Diabetes mellitus:

Lead poisoning:

Spinal cord lesions:

Botulism (infant):

Medication-induced:

Behavioral/psychiatric:

Long-Term Plan — Maintenance, Tapering, and Relapse Prevention

— Continue PEG (or chosen agent) at effective dose until child has consistent painless soft stools and no soiling for at least 2 months, then taper slowly over weeks to months.

— Total treatment duration typically 6–24 months; longer in severe or longstanding cases.

— Premature discontinuation is the #1 reason for relapse — emphasize this at every visit.

— Reduce PEG by ~25% every 2–4 weeks while monitoring stool consistency.

— If hard stools or soiling return, return to prior effective dose for another 2–3 months before retrying.

— Scheduled toilet sits 5–10 min after meals, 2–3 times daily, with footstool for hip flexion (>90° squat position).

— Reward systems (stickers, charts) for sitting, not for producing stool — reduces performance pressure.

— Bristol stool chart for older children to self-monitor.

— Age-appropriate fluids, fiber per age (~age + 5 to age + 10 grams/day), normal balanced diet.

— Cow's milk <24 oz/day in toddlers.

— Avoid restrictive "constipation diets" — not evidence-based and reduce quality of life.

— Letter authorizing unrestricted bathroom access, ability to carry water, and excuse from public restroom restrictions.

— Travel, illness, dietary change, school transitions, family stressors, summer schedule disruption.

— Have a written "rescue plan": resume full disimpaction dose at first signs of recurrence.

Step 3 management: When a child with previously controlled constipation relapses after stopping PEG, restart at the disimpaction dose for 3–6 days, then resume maintenance — and counsel families that stopping medication too early is the most common preventable cause of relapse, not "laxative dependence" (a common parental misconception worth proactively dispelling).

Maintenance duration:

Tapering strategy:

Behavioral plan reinforcement:

Dietary maintenance:

School accommodations:

Relapse triggers to anticipate:

Follow-Up, Monitoring, and Counseling Cadence

— 2 weeks after starting therapy: confirm disimpaction success, titrate maintenance dose, review behavioral plan, address parental questions.

— Monthly for 3 months: assess stool diary, soiling episodes, adherence, side effects.

— Every 3–6 months thereafter until tapered off and 6 months symptom-free.

— Earlier return if relapse or red flags emerge.

— Stool frequency and Bristol consistency (goal: ≥4 stools/week, Bristol 3–4).

— Soiling episodes per week.

— Pain or blood with stooling.

— Growth (height, weight, BMI at every visit).

— Adherence to PEG and behavioral plan.

— School performance, social functioning, mood.

— Simple home log of frequency, consistency, soiling, and medication dose — empowers family and clinician.

— Reframe encopresis as involuntary; eliminate punishment.

— Set realistic expectations (months to years of treatment).

— Explain PEG safety and lack of dependence/tolerance.

— Encourage active toilet training pause if currently a stressor.

— Address parental guilt and family dynamics.

— Provide written action plan: at first hard stool or soiling, double dose PEG × 3 days, return to clinic if not improved in 1 week.

— Use PedsQL or symptom-specific tools; soiling has measurable impact on QoL comparable to chronic asthma or IBD.

CCS pearl: Order "follow-up in 2 weeks" after starting disimpaction, "stool diary", and "counsel parents on behavioral plan, medication safety, and expected duration of therapy" — the CCS clock rewards structured longitudinal management with appropriate intervals, not single-visit fixes.

Visit cadence (ambulatory Step 3 framework):

Monitoring parameters:

Stool diary:

Counseling priorities:

Anticipatory guidance for relapse:

Quality-of-life screening:

Ethical, Legal, and Patient Safety Considerations

— Children with soiling are frequently punished, shamed, or labeled "lazy" or "manipulative."

— Clinician's duty: explicitly counsel families that soiling is involuntary overflow, document this counseling, and intervene when punishment is occurring.

— Sudden constipation with anal trauma, bruising, STI exposure, or out-of-proportion withholding fear must prompt assessment for sexual abuse and mandated reporting per state law.

— Functional constipation does not itself indicate abuse, but unexplained perianal findings do.

— When in doubt, consult child protection team; document objective findings.

— PEG 3350 is widely used long-term in pediatrics with strong safety data but is technically off-label for >7 days/chronic use — disclose this and discuss safety evidence.

— Document parental understanding of duration and rationale.

— Sodium phosphate enemas in young children or those with renal impairment — black-box-level risk of fatal electrolyte derangement; avoid.

— Mineral oil aspiration in <1 year or children with swallowing dysfunction → lipoid pneumonia.

— Forceful or repeated enemas by frustrated caregivers — risk of rectal trauma and perforation; provide clear, written instructions and limit home enema use.

— Discharge from inpatient disimpaction without scheduled outpatient follow-up and written maintenance plan → near-universal relapse.

— Always communicate plan to PCP and provide family with written instructions including dose, duration, red flags, and follow-up timing.

— Screen privately for laxative misuse (eating disorders), sexual abuse, substance use; respect confidentiality within state minor consent laws while balancing safety reporting obligations.

Board pearl: Always document the encopresis counseling conversation — that soiling is involuntary, not behavioral — because failure to convey this leads to ongoing punishment, treatment non-adherence, and identifiable harm; this is a recognized quality and patient-safety standard in pediatric constipation care.

Reframing encopresis to prevent emotional harm:

Mandatory reporting / abuse considerations:

Informed consent for off-label use:

Patient safety pitfalls:

Transition-of-care risks:

Adolescent confidentiality:

High-Yield Associations and Rapid-Fire Facts

Step 3 management: Memorize the PEG 3350 dose ranges, the Hirschsprung red flags, and the sodium phosphate enema contraindication — these three buckets cover the majority of testable pediatric constipation decision points.

Delayed meconium >48 hr → Hirschsprung disease.

Empty rectum + squirt sign → Hirschsprung.

Loaded rectum + encopresis → functional constipation.

Rectal prolapse in a child → check sweat chloride (CF).

Constipation + descending hypotonia in infant <1 yr → infant botulism, give BabyBIG, avoid aminoglycosides.

Constipation + sacral dimple/hair tuft → tethered cord, order spinal MRI.

Constipation + growth failure → check TSH, tTG IgA, sweat chloride.

Constipation + nocturnal enuresis or recurrent UTIs → treat constipation first (bowel-bladder dysfunction).

Sodium phosphate enema in <2 yr or CKD → can kill (hyperphosphatemia, hypocalcemia, hypernatremia).

Mineral oil in <1 yr → lipoid pneumonia risk.

Cow's milk >24 oz/day in toddler → modifiable constipation cause.

PEG 3350 disimpaction dose → 1–1.5 g/kg/day × 3–6 days.

PEG 3350 maintenance dose → 0.4–0.8 g/kg/day, titrate to soft daily stool.

Duration of therapy → minimum 6 months, continue ≥2 months after symptoms resolve.

Rome IV criteria → ≥2 of 6 features for ≥1 month (<4 yr) or ≥2 months (≥4 yr).

Definitive Hirschsprung dx → rectal suction biopsy showing absent ganglion cells + hypertrophied nerves.

Anorectal manometry finding in Hirschsprung → absent RAIR.

Down syndrome → screen for Hirschsprung and hypothyroidism.

Infant dyschezia → benign, no laxatives, no rectal stimulation, resolves by 9 mo.

First-line laxative all ages >6 mo → PEG 3350.

First-line in <6 mo → lactulose, glycerin suppository, sorbitol juices after 4 mo.

Hirschsprung-associated enterocolitis → fever + distention + explosive bloody diarrhea, emergency.

DIOS in CF → high-volume PEG or Gastrografin enema, optimize enzymes.

Board Question Stem Patterns

— 4-year-old, painful stooling for 6 months, hides behind couch, soils underwear daily, palpable suprapubic mass, fissure on exam. Best next step: PEG 3350 disimpaction + parental education on encopresis. Distractors: abdominal x-ray, abuse evaluation, antidiarrheals, dietary fiber alone.

— Term newborn, no meconium at 60 hr, bilious vomiting, distended abdomen, empty rectum with explosive stool on DRE withdrawal. Best next step: contrast enema + rectal suction biopsy; pediatric surgery consult.

— 5-month-old with 1 week of constipation, now poor feeding, weak cry, hypotonia, decreased gag. Mom uses local honey. Best next step: admit, supportive care, BabyBIG; stool for toxin/spores; avoid aminoglycosides.

— Toddler with chronic constipation, midline sacral dimple with hair tuft, abnormal gait. Best next step: lumbosacral spine MRI.

— Child with chronic constipation, rectal prolapse, FTT, recurrent sinopulmonary infections. Best next step: sweat chloride test.

— Adolescent with new constipation, fatigue, weight gain, bradycardia, delayed reflexes. Best next step: TSH and free T4.

— Child on PEG 3 months, parents stopped when stools became soft, now relapsed with soiling. Best next step: resume disimpaction dose then maintenance for ≥6 months total, reinforce that early discontinuation causes relapse.

— 18-month-old with severe impaction; option to give sodium phosphate enema. Correct answer: avoid sodium phosphate enema (toddler/CKD); use oral PEG or saline enema.

— 7-year-old with recurrent UTIs and daytime/nighttime enuresis, also has hard stools q4–5 days. Best next step: treat constipation first before urologic workup.

Board pearl: When the stem mentions encopresis, the answer is almost always functional constipation with overflow — choose PEG disimpaction and behavioral counseling, not abuse workup, antidiarrheals, or Hirschsprung biopsy.

Stem A — Classic functional constipation:

Stem B — Hirschsprung in neonate:

Stem C — Infant botulism:

Stem D — Spinal dysraphism:

Stem E — Cystic fibrosis presentation:

Stem F — Hypothyroidism:

Stem G — Treatment failure:

Stem H — Avoidance question:

Stem I — Bowel-bladder dysfunction:

One-Line Recap

Pediatric constipation is overwhelmingly functional (>95%), diagnosed clinically by Rome IV criteria, and treated with parental education, PEG 3350 disimpaction followed by months of maintenance therapy plus scheduled toilet sits — while red flags such as delayed meconium, FTT, sacral anomalies, or abnormal neuro exam must trigger evaluation for Hirschsprung disease, spinal dysraphism, hypothyroidism, celiac, or cystic fibrosis.

Step 3 management: A child with painful stooling and soiling needs PEG, parents, and patience — not panels, plain films, or punishment; success is measured in months of consistent follow-up, not days, and the most common error on both boards and in practice is stopping therapy too soon.

Diagnosis: clinical (Rome IV); no routine labs or imaging; targeted workup only with red flags.

First-line therapy: PEG 3350 disimpaction (1–1.5 g/kg/day × 3–6 days) → maintenance (0.4–0.8 g/kg/day) titrated to soft daily stool, continued ≥6 months and ≥2 months past symptom resolution.

Behavioral plan is non-negotiable: demystify encopresis as involuntary overflow, scheduled post-meal toilet sits with footstool, reward sitting (not stooling), limit cow's milk to <24 oz/day, age-appropriate fiber/fluid.

Red flags to escalate: delayed meconium >48 hr (Hirschsprung), FTT (celiac/CF/thyroid), sacral dimple/hair tuft/abnormal neuro (tethered cord), rectal prolapse (CF), infant constipation with hypotonia and weak cry (botulism), recurrent UTIs/enuresis (bowel-bladder dysfunction — treat bowel first), and any abnormal perianal exam (anatomic anomaly or abuse).

Safety must-knows: avoid sodium phosphate enemas in <2 yr and CKD; avoid mineral oil in <1 yr; never frame encopresis as misbehavior; document counseling and provide written discharge plan to prevent transition-of-care relapse.